Nova Eye Medical Ltd. (ELXMF)
0.0143
0.00 (0.00%)
USD |
OTCM |
Aug 28, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 4.075M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -85.70% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | 0.1719 |
| Price to Book Value | -- |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | -- |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 99.91% |
Profile
| Nova Eye Medical Ltd. engages in developing suite of novel ophthalmic treatment technologies. It operates through the following segments: Faster Growing (iTrack), Emerging (2RT), and Core Ophthalmic Mark (Lasers and Ultrasounds). The iTrack segment offers catheter device that dilates the ocular structures compromised by glaucoma. The 2RT segment includes patent-protected with significant lead on competition and a per-use recurring fee business model. The Lasers and Ultrasounds segment represents testimony to the strength of the Ellex brand and was driven by growth in sales of the high-margin Ellex Tango and Ellex Tango Reflex glaucoma lasers. The company was founded by Giuseppe Canala and Victor Previn in 1985 and is headquartered in Kent Town, Australia. |
| URL | http://www.nova-eye.com |
| Investor Relations URL | N/A |
| HQ State/Province | South Australia (SA) |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Small Cap Core |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jul. 21, 2020 |
Profile
| Nova Eye Medical Ltd. engages in developing suite of novel ophthalmic treatment technologies. It operates through the following segments: Faster Growing (iTrack), Emerging (2RT), and Core Ophthalmic Mark (Lasers and Ultrasounds). The iTrack segment offers catheter device that dilates the ocular structures compromised by glaucoma. The 2RT segment includes patent-protected with significant lead on competition and a per-use recurring fee business model. The Lasers and Ultrasounds segment represents testimony to the strength of the Ellex brand and was driven by growth in sales of the high-margin Ellex Tango and Ellex Tango Reflex glaucoma lasers. The company was founded by Giuseppe Canala and Victor Previn in 1985 and is headquartered in Kent Town, Australia. |
| URL | http://www.nova-eye.com |
| Investor Relations URL | N/A |
| HQ State/Province | South Australia (SA) |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Small Cap Core |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jul. 21, 2020 |